<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240702100904
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240702100904" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 02 Jul 2024 14:09:06 +0000</lastbuilddate>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A New Molecular Axis to Tackle the Development of Abdominal Aortic Aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950116/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):47-48. doi: 10.1161/CIRCULATIONAHA.124.069916. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950116/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950116</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069916>10.1161/CIRCULATIONAHA.124.069916</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950116</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Leonardo Elia</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A New Molecular Axis to Tackle the Development of Abdominal Aortic Aneurysm</dc:title>
<dc:identifier>pmid:38950116</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069916</dc:identifier>
</item>
<item>
<title>Correction to: Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e20. doi: 10.1161/CIR.0000000000001267. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950115</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001267>10.1161/CIR.0000000000001267</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950115</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial</dc:title>
<dc:identifier>pmid:38950115</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001267</dc:identifier>
</item>
<item>
<title>Response by Berry et al to Letter Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e5-e6. doi: 10.1161/CIRCULATIONAHA.124.069708. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950114</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069708>10.1161/CIRCULATIONAHA.124.069708</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950114</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Novalia P Sidik</dc:creator>
<dc:creator>Margaret B McEntegart</dc:creator>
<dc:creator>CorCTA Investigators</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Berry et al to Letter Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38950114</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069708</dc:identifier>
</item>
<item>
<title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):1-3. doi: 10.1161/CIR.0000000000001271. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950113</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001271>10.1161/CIR.0000000000001271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950113</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38950113</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001271</dc:identifier>
</item>
<item>
<title>Health and Hope for Everyone, Everywhere, Starts With Access to Health Care: The Role of Medicaid Expansion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e1-e2. doi: 10.1161/CIRCULATIONAHA.124.070084. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950112</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070084>10.1161/CIRCULATIONAHA.124.070084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950112</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Dan Jones</dc:creator>
<dc:creator>Cheryl Pegus</dc:creator>
<dc:creator>Janay C Johnson</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Health and Hope for Everyone, Everywhere, Starts With Access to Health Care: The Role of Medicaid Expansion</dc:title>
<dc:identifier>pmid:38950112</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070084</dc:identifier>
</item>
<item>
<title>Letter by Nishi et al Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e3-e4. doi: 10.1161/CIRCULATIONAHA.124.068798. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950111</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068798>10.1161/CIRCULATIONAHA.124.068798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950111</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeshi Nishi</dc:creator>
<dc:creator>Yuichi Saito</dc:creator>
<dc:creator>Yoshio Kobayashi</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Nishi et al Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38950111</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068798</dc:identifier>
</item>
<item>
<title>Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):62-79. doi: 10.1161/CIRCULATIONAHA.124.068885. Epub 2024 Jul 1.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol targets or triggers to initiate treatment change, consistent targets for apoB are lacking. In this review, we synthesize existing data regarding the epidemiology of apoB by comparing guideline recommendations regarding use of apoB measurement, describing population percentiles of apoB relative to low-density lipoprotein cholesterol levels, summarizing studies of discordance between low-density lipoprotein cholesterol and apoB levels, and evaluating apoB levels in clinical trials of lipid-lowering therapy to guide potential treatment targets. We propose evidence-guided apoB thresholds for use in cholesterol management and clinical care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950110</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068885>10.1161/CIRCULATIONAHA.124.068885</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950110</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Diana De Oliveira-Gomes</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Anand Rohatgi</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice</dc:title>
<dc:identifier>pmid:38950110</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068885</dc:identifier>
</item>
<item>
<title>Ablation of Cardiac Arrhythmias: Past, Present, and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):4-6. doi: 10.1161/CIRCULATIONAHA.124.068298. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950109</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068298>10.1161/CIRCULATIONAHA.124.068298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950109</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Hakan Oral</dc:creator>
<dc:creator>Fred Morady</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ablation of Cardiac Arrhythmias: Past, Present, and Future</dc:title>
<dc:identifier>pmid:38950109</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068298</dc:identifier>
</item>
<item>
<title>Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):82-85. doi: 10.1161/CIRCULATIONAHA.123.066709. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38950107</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066709>10.1161/CIRCULATIONAHA.123.066709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950107</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro Gabriel Melo de Barros E Silva</dc:creator>
<dc:creator>Ariane Vieira Scarlatelli Macedo</dc:creator>
<dc:creator>Bruna Bronhara</dc:creator>
<dc:creator>Lucas Petri Damiani</dc:creator>
<dc:creator>Lilian Mazza Barbosa</dc:creator>
<dc:creator>Nathália Rodrigues Lopes</dc:creator>
<dc:creator>Mayra Akimi Suiama</dc:creator>
<dc:creator>Murillo O Antunes</dc:creator>
<dc:creator>Mariana Raquel Gonçalves</dc:creator>
<dc:creator>Otávio Celso Eluf Gebara</dc:creator>
<dc:creator>Priscilla de Aquino Martins</dc:creator>
<dc:creator>Mariana Galvão Ribeiro</dc:creator>
<dc:creator>João Batista de Moura Xavier de Moraes</dc:creator>
<dc:creator>Valéria Cristina Resende Aguiar</dc:creator>
<dc:creator>Alexandre B Cavalcanti</dc:creator>
<dc:creator>Regis G Rosa</dc:creator>
<dc:creator>Otavio Berwanger</dc:creator>
<dc:creator>Viviane C Veiga</dc:creator>
<dc:creator>Luciano C P Azevedo</dc:creator>
<dc:creator>Eduardo Ramacciotti</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Alvaro Avezum</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Coalition COVID-19 Brazil Investigators</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38950107</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066709</dc:identifier>
</item>
<item>
<title>Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38946541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ARRDC4 serves as a regulator of hyperglycemia-induced toxicities toward cardiac and skeletal muscle, revealing a new molecular framework that connects hyperglycemia to cardiac/skeletal myopathy to exercise intolerance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 1. doi: 10.1161/CIRCRESAHA.123.323158. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exercise intolerance is an independent predictor of poor prognosis in diabetes. The underlying mechanism of the association between hyperglycemia and exercise intolerance remains undefined. We recently demonstrated that the interaction between ARRDC4 (arrestin domain-containing protein 4) and GLUT1 (glucose transporter 1) regulates cardiac metabolism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether this mechanism broadly impacts diabetic complications, we investigated the role of ARRDC4 in the pathogenesis of diabetic cardiac and skeletal myopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: High glucose promoted translocation of MondoA into the nucleus, which upregulated <i>Arrdc4</i> transcriptional expression, increased lysosomal GLUT1 trafficking, and blocked glucose transport in cardiomyocytes, forming a feedback mechanism. This role of <i>ARRDC4</i> was confirmed in human muscular cells from type 2 diabetic patients. Prolonged hyperglycemia upregulated myocardial <i>Arrdc4</i> expression in multiple types of mouse models of diabetes. We then analyzed hyperglycemia-induced cardiac and skeletal muscle abnormalities in insulin-deficient mice. Hyperglycemia increased advanced glycation end-products and elicited oxidative and endoplasmic reticulum stress leading to apoptosis in the heart and peripheral muscle. However, deletion of <i>Arrdc4</i> augmented tissue glucose transport and mitochondrial respiration, protecting the heart and muscle from tissue damage. Stress hemodynamic analysis and treadmill exhaustion test uncovered that <i>Arrdc4</i>-knockout mice had greater cardiac inotropic/chronotropic reserve with higher exercise endurance than wild-type (WT) animals under diabetes. While multiple organs were involved in the mechanism, cardiac-specific overexpression (beyond levels observed during diabetes) using adenoassociated virus suggests that high levels of myocardial <i>ARRDC4</i> have the potential to contribute to exercise intolerance by interfering with cardiac metabolism through its interaction with GLUT1 in diabetes. Importantly, the <i>ARRDC4</i> mutation mouse line exhibited greater exercise tolerance, showing the potential therapeutic impact on diabetic cardiomyopathy by disrupting the interaction between ARRDC4 and GLUT1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ARRDC4 serves as a regulator of hyperglycemia-induced toxicities toward cardiac and skeletal muscle, revealing a new molecular framework that connects hyperglycemia to cardiac/skeletal myopathy to exercise intolerance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38946541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38946541</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323158>10.1161/CIRCRESAHA.123.323158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38946541</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yoshinobu Nakayama</dc:creator>
<dc:creator>Satoru Kobayashi</dc:creator>
<dc:creator>Aliya Masihuddin</dc:creator>
<dc:creator>Syed Amir Abdali</dc:creator>
<dc:creator>A M Pramodh Bandara Seneviratne</dc:creator>
<dc:creator>Sachiyo Ishii</dc:creator>
<dc:creator>Jun Iida</dc:creator>
<dc:creator>Qiangrong Liang</dc:creator>
<dc:creator>Jun Yoshioka</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes</dc:title>
<dc:identifier>pmid:38946541</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323158</dc:identifier>
</item>
<item>
<title>Temporal dynamics of woolly mammoth genome erosion prior to extinction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>A number of species have recently recovered from near-extinction. Although these species have avoided the immediate extinction threat, their long-term viability remains precarious due to the potential genetic consequences of population declines, which are poorly understood on a timescale beyond a few generations. Woolly mammoths (Mammuthus primigenius) became isolated on Wrangel Island around 10,000 years ago and persisted for over 200 generations before becoming extinct around 4,000 years ago....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 17:S0092-8674(24)00577-4. doi: 10.1016/j.cell.2024.05.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A number of species have recently recovered from near-extinction. Although these species have avoided the immediate extinction threat, their long-term viability remains precarious due to the potential genetic consequences of population declines, which are poorly understood on a timescale beyond a few generations. Woolly mammoths (Mammuthus primigenius) became isolated on Wrangel Island around 10,000 years ago and persisted for over 200 generations before becoming extinct around 4,000 years ago. To study the evolutionary processes leading up to the mammoths' extinction, we analyzed 21 Siberian woolly mammoth genomes. Our results show that the population recovered quickly from a severe bottleneck and remained demographically stable during the ensuing six millennia. We find that mildly deleterious mutations gradually accumulated, whereas highly deleterious mutations were purged, suggesting ongoing inbreeding depression that lasted for hundreds of generations. The time-lag between demographic and genetic recovery has wide-ranging implications for conservation management of recently bottlenecked populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38942016</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.033>10.1016/j.cell.2024.05.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942016</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marianne Dehasque</dc:creator>
<dc:creator>Hernán E Morales</dc:creator>
<dc:creator>David Díez-Del-Molino</dc:creator>
<dc:creator>Patrícia Pečnerová</dc:creator>
<dc:creator>J Camilo Chacón-Duque</dc:creator>
<dc:creator>Foteini Kanellidou</dc:creator>
<dc:creator>Héloïse Muller</dc:creator>
<dc:creator>Valerii Plotnikov</dc:creator>
<dc:creator>Albert Protopopov</dc:creator>
<dc:creator>Alexei Tikhonov</dc:creator>
<dc:creator>Pavel Nikolskiy</dc:creator>
<dc:creator>Gleb K Danilov</dc:creator>
<dc:creator>Maddalena Giannì</dc:creator>
<dc:creator>Laura van der Sluis</dc:creator>
<dc:creator>Tom Higham</dc:creator>
<dc:creator>Peter D Heintzman</dc:creator>
<dc:creator>Nikolay Oskolkov</dc:creator>
<dc:creator>M Thomas P Gilbert</dc:creator>
<dc:creator>Anders Götherström</dc:creator>
<dc:creator>Tom van der Valk</dc:creator>
<dc:creator>Sergey Vartanyan</dc:creator>
<dc:creator>Love Dalén</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Temporal dynamics of woolly mammoth genome erosion prior to extinction</dc:title>
<dc:identifier>pmid:38942016</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.033</dc:identifier>
</item>
<item>
<title>The extracellular matrix integrates mitochondrial homeostasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>Cellular homeostasis is intricately influenced by stimuli from the microenvironment, including signaling molecules, metabolites, and pathogens. Functioning as a signaling hub within the cell, mitochondria integrate information from various intracellular compartments to regulate cellular signaling and metabolism. Multiple studies have shown that mitochondria may respond to various extracellular signaling events. However, it is less clear how changes in the extracellular matrix (ECM) can impact...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 24:S0092-8674(24)00638-X. doi: 10.1016/j.cell.2024.05.057. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular homeostasis is intricately influenced by stimuli from the microenvironment, including signaling molecules, metabolites, and pathogens. Functioning as a signaling hub within the cell, mitochondria integrate information from various intracellular compartments to regulate cellular signaling and metabolism. Multiple studies have shown that mitochondria may respond to various extracellular signaling events. However, it is less clear how changes in the extracellular matrix (ECM) can impact mitochondrial homeostasis to regulate animal physiology. We find that ECM remodeling alters mitochondrial homeostasis in an evolutionarily conserved manner. Mechanistically, ECM remodeling triggers a TGF-β response to induce mitochondrial fission and the unfolded protein response of the mitochondria (UPR<sup>MT</sup>). At the organismal level, ECM remodeling promotes defense of animals against pathogens through enhanced mitochondrial stress responses. We postulate that this ECM-mitochondria crosstalk represents an ancient immune pathway, which detects infection- or mechanical-stress-induced ECM damage, thereby initiating adaptive mitochondria-based immune and metabolic responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38942015</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.057>10.1016/j.cell.2024.05.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942015</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Hanlin Zhang</dc:creator>
<dc:creator>C Kimberly Tsui</dc:creator>
<dc:creator>Gilberto Garcia</dc:creator>
<dc:creator>Larry K Joe</dc:creator>
<dc:creator>Haolun Wu</dc:creator>
<dc:creator>Ayane Maruichi</dc:creator>
<dc:creator>Wudi Fan</dc:creator>
<dc:creator>Sentibel Pandovski</dc:creator>
<dc:creator>Peter H Yoon</dc:creator>
<dc:creator>Brant M Webster</dc:creator>
<dc:creator>Jenni Durieux</dc:creator>
<dc:creator>Phillip A Frankino</dc:creator>
<dc:creator>Ryo Higuchi-Sanabria</dc:creator>
<dc:creator>Andrew Dillin</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The extracellular matrix integrates mitochondrial homeostasis</dc:title>
<dc:identifier>pmid:38942015</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.057</dc:identifier>
</item>
<item>
<title>Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>Neuroimmune interactions mediate intercellular communication and underlie critical brain functions. Microglia, CNS-resident macrophages, modulate the brain through direct physical interactions and the secretion of molecules. One such secreted factor, the complement protein C1q, contributes to complement-mediated synapse elimination in both developmental and disease models, yet brain C1q protein levels increase significantly throughout aging. Here, we report that C1q interacts with neuronal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 24:S0092-8674(24)00639-1. doi: 10.1016/j.cell.2024.05.058. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Neuroimmune interactions mediate intercellular communication and underlie critical brain functions. Microglia, CNS-resident macrophages, modulate the brain through direct physical interactions and the secretion of molecules. One such secreted factor, the complement protein C1q, contributes to complement-mediated synapse elimination in both developmental and disease models, yet brain C1q protein levels increase significantly throughout aging. Here, we report that C1q interacts with neuronal ribonucleoprotein (RNP) complexes in an age-dependent manner. Purified C1q protein undergoes RNA-dependent liquid-liquid phase separation (LLPS) in vitro, and the interaction of C1q with neuronal RNP complexes in vivo is dependent on RNA and endocytosis. Mice lacking C1q have age-specific alterations in neuronal protein synthesis in vivo and impaired fear memory extinction. Together, our findings reveal a biophysical property of C1q that underlies RNA- and age-dependent neuronal interactions and demonstrate a role of C1q in critical intracellular neuronal processes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38942014</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.058>10.1016/j.cell.2024.05.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942014</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicole Scott-Hewitt</dc:creator>
<dc:creator>Matthew Mahoney</dc:creator>
<dc:creator>Youtong Huang</dc:creator>
<dc:creator>Nils Korte</dc:creator>
<dc:creator>T Yvanka de Soysa</dc:creator>
<dc:creator>Daniel K Wilton</dc:creator>
<dc:creator>Emily Knorr</dc:creator>
<dc:creator>Kevin Mastro</dc:creator>
<dc:creator>Allison Chang</dc:creator>
<dc:creator>Allison Zhang</dc:creator>
<dc:creator>David Melville</dc:creator>
<dc:creator>Monica Schenone</dc:creator>
<dc:creator>Christina Hartigan</dc:creator>
<dc:creator>Beth Stevens</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain</dc:title>
<dc:identifier>pmid:38942014</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.058</dc:identifier>
</item>
<item>
<title>Stress-dependent condensate formation regulated by the ubiquitin-related modifier Urm1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>The ability of proteins and RNA to coalesce into phase-separated assemblies, such as the nucleolus and stress granules, is a basic principle in organizing membraneless cellular compartments. While the constituents of biomolecular condensates are generally well documented, the mechanisms underlying their formation under stress are only partially understood. Here, we show in yeast that covalent modification with the ubiquitin-like modifier Urm1 promotes the phase separation of a wide range of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 26:S0092-8674(24)00649-4. doi: 10.1016/j.cell.2024.06.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ability of proteins and RNA to coalesce into phase-separated assemblies, such as the nucleolus and stress granules, is a basic principle in organizing membraneless cellular compartments. While the constituents of biomolecular condensates are generally well documented, the mechanisms underlying their formation under stress are only partially understood. Here, we show in yeast that covalent modification with the ubiquitin-like modifier Urm1 promotes the phase separation of a wide range of proteins. We find that the drop in cellular pH induced by stress triggers Urm1 self-association and its interaction with both target proteins and the Urm1-conjugating enzyme Uba4. Urmylation of stress-sensitive proteins promotes their deposition into stress granules and nuclear condensates. Yeast cells lacking Urm1 exhibit condensate defects that manifest in reduced stress resilience. We propose that Urm1 acts as a reversible molecular "adhesive" to drive protective phase separation of functionally critical proteins under cellular stress.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38942013</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.009>10.1016/j.cell.2024.06.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942013</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucas V Cairo</dc:creator>
<dc:creator>Xiaoyu Hong</dc:creator>
<dc:creator>Martin B D Müller</dc:creator>
<dc:creator>Patricia Yuste-Checa</dc:creator>
<dc:creator>Chandhuru Jagadeesan</dc:creator>
<dc:creator>Andreas Bracher</dc:creator>
<dc:creator>Sae-Hun Park</dc:creator>
<dc:creator>Manajit Hayer-Hartl</dc:creator>
<dc:creator>F Ulrich Hartl</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stress-dependent condensate formation regulated by the ubiquitin-related modifier Urm1</dc:title>
<dc:identifier>pmid:38942013</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.009</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: a penULTIMATE frontier for optimal antiplatelet therapy after drug-eluting stenting in acute coronary syndromes?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38941346/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 28:ehae367. doi: 10.1093/eurheartj/ehae367. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38941346/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38941346</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae367>10.1093/eurheartj/ehae367</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38941346</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: a penULTIMATE frontier for optimal antiplatelet therapy after drug-eluting stenting in acute coronary syndromes?</dc:title>
<dc:identifier>pmid:38941346</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae367</dc:identifier>
</item>
<item>
<title>Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies-a review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38941344/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>Acute ST-elevation myocardial infarction (STEMI) and acute ischaemic stroke (AIS) share a number of similarities. However, important differences in pathophysiology demand a disease-tailored approach. In both conditions, fast treatment plays a crucial role as ischaemia and eventually infarction develop rapidly. Furthermore, in both fields, the introduction of fibrinolytic treatments historically preceded the implementation of endovascular techniques. However, in contrast to STEMI, only a minority...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 28:ehae371. doi: 10.1093/eurheartj/ehae371. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Acute ST-elevation myocardial infarction (STEMI) and acute ischaemic stroke (AIS) share a number of similarities. However, important differences in pathophysiology demand a disease-tailored approach. In both conditions, fast treatment plays a crucial role as ischaemia and eventually infarction develop rapidly. Furthermore, in both fields, the introduction of fibrinolytic treatments historically preceded the implementation of endovascular techniques. However, in contrast to STEMI, only a minority of AIS patients will eventually be considered eligible for reperfusion treatment. Non-invasive cerebral imaging always precedes cerebral angiography and thrombectomy, whereas coronary angiography is not routinely preceded by non-invasive cardiac imaging in patients with STEMI. In the late or unknown time window, the presence of specific patterns on brain imaging may help identify AIS patients who benefit most from reperfusion treatment. For STEMI, a uniform time window for reperfusion up to 12 h after symptom onset, based on old placebo-controlled trials, is still recommended in guidelines and generally applied. Bridging fibrinolysis preceding endovascular treatment still remains the mainstay of reperfusion treatment in AIS, while primary percutaneous coronary intervention is the strategy of choice in STEMI. Shortening ischaemic times by fine-tuning collaboration networks between ambulances, community hospitals, and tertiary care hospitals, optimizing bridging fibrinolysis, and reducing ischaemia-reperfusion injury are important topics for further research. The aim of this review is to provide insights into the common as well as diverging pathophysiology behind current reperfusion strategies and to explore new ways to enhance their clinical benefit.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38941344/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38941344</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae371>10.1093/eurheartj/ehae371</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38941344</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lauranne Scheldeman</dc:creator>
<dc:creator>Peter Sinnaeve</dc:creator>
<dc:creator>Gregory W Albers</dc:creator>
<dc:creator>Robin Lemmens</dc:creator>
<dc:creator>Frans Van de Werf</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies-a review</dc:title>
<dc:identifier>pmid:38941344</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae371</dc:identifier>
</item>
<item>
<title>A focus on three hot topics: atrial fibrillation, obesity, and climate change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38941334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 28;45(24):2105-2108. doi: 10.1093/eurheartj/ehae380.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38941334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38941334</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae380>10.1093/eurheartj/ehae380</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38941334</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A focus on three hot topics: atrial fibrillation, obesity, and climate change</dc:title>
<dc:identifier>pmid:38941334</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae380</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: an ounce of PREVENTion is worth more than a pound of stents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38941317/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 28:ehae385. doi: 10.1093/eurheartj/ehae385. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38941317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38941317</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae385>10.1093/eurheartj/ehae385</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38941317</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: an ounce of PREVENTion is worth more than a pound of stents</dc:title>
<dc:identifier>pmid:38941317</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae385</dc:identifier>
</item>
<item>
<title>Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38940005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: After adjustment for potential confounding factors, presence of AF was associated with higher mortality than no AF in our cohort of patients with cardiac implantable electronic devices. Among those with AF, nonparoxysmal AF was associated with the greatest risk of mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069757. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current estimates of atrial fibrillation (AF)-associated mortality rely on claims- or clinical-derived diagnoses of AF, limit AF to a binary entity, or are confounded by comorbidities. The objective of the present study is to assess the association between device-recognized AF and mortality among patients with cardiac implantable electronic devices capable of sensitive and continuous atrial arrhythmia detection. Secondary outcomes include relative mortality among cohorts with no AF, paroxysmal AF, persistent AF, and permanent AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the deidentified Optum Clinformatics US claims database (2015 to 2020) linked to the Medtronic CareLink database, we identified individuals with a cardiac implantable electronic device who transmitted data ≥6 months after implantation. AF burden was assessed during the first 6 months after implantation (baseline period). Subsequent mortality, assessed from claims data, was compared between patients with and those without AF, with adjustment for age, geographic region, insurance type, Charlson Comorbidity Index, and implantation year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 21 391 patients (age, 72.9±10.9 years; 56.3% male) analyzed, 7798 (36.5%) had device-recognized AF. During a mean of 22.4±12.9 months (median, 20.1 [12.8-29.7] months) of follow-up, the overall incidence of mortality was 13.5%. Patients with AF had higher adjusted all-cause mortality than patients without AF (hazard ratio, 1.29 [95% CI, 1.20-1.39]; <i>P</i>&lt;0.001). Among those with AF, patients with nonparoxysmal AF had the greatest risk of mortality (persistent AF versus paroxysmal AF: hazard ratio, 1.36 [95% CI, 1.18-1.58]; <i>P</i>&lt;.001; permanent AF versus paroxysmal AF: hazard ratio, 1.23 [95% CI, 1.14-1.34]; <i>P</i>&lt;.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After adjustment for potential confounding factors, presence of AF was associated with higher mortality than no AF in our cohort of patients with cardiac implantable electronic devices. Among those with AF, nonparoxysmal AF was associated with the greatest risk of mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38940005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38940005</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069757>10.1161/CIRCULATIONAHA.124.069757</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38940005</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Graham Peigh</dc:creator>
<dc:creator>Jiani Zhou</dc:creator>
<dc:creator>Sarah C Rosemas</dc:creator>
<dc:creator>Anthony I Roberts</dc:creator>
<dc:creator>Colleen Longacre</dc:creator>
<dc:creator>Katherine Trinh</dc:creator>
<dc:creator>Tanvi Nayak</dc:creator>
<dc:creator>Dana Soderlund</dc:creator>
<dc:creator>Rod S Passman</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices</dc:title>
<dc:identifier>pmid:38940005</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069757</dc:identifier>
</item>
<item>
<title>Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: There is significant variability in WM among status-1A patients. Potential refinements to current allocation system should factor in the increased WM risk we identified in patients supported by extracorporeal membrane oxygenation or mechanical ventilation, single ventricle congenital heart disease on VAD support and small children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.123.068189. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Waitlist mortality (WM) remains elevated in pediatric heart transplantation. Allocation policy is a potential tool to help improve WM. This study aims to identify patients at highest risk for WM to potentially inform future allocation policy changes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Pediatric Heart Transplant Society database was queried for patients &lt;18 years of age indicated for heart transplantation between January 1, 2010 to December 31, 2021. <i>Waitlist mortality</i> was defined as death while awaiting transplant or removal from the waitlist due to clinical deterioration. Because WM is low after the first year, analysis was limited to the first 12 months on the heart transplant list. Kaplan-Meier analysis and log-rank testing was conducted to compare unadjusted survival between groups. Cox proportional hazard models were created to determine risk factors for WM. Subgroup analysis was performed for status 1A patients based on body surface area (BSA) at time of listing, cardiac diagnosis, and presence of mechanical circulatory support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total 5974 children met study criteria of which 3928 were status 1A, 1012 were status 1B, 963 were listed status 2, and 65 were listed status 7. Because of the significant burden of WM experienced by 1A patients, further analysis was performed in only patients indicated as 1A. Within that group of patients, those with smaller size and lower eGFR had higher WM, whereas those patients without congenital heart disease or support from a ventricular assist device (VAD) at time of listing had decreased WM. In the smallest size cohort, cardiac diagnoses other than dilated cardiomyopathy were risk factors for WM. Previous cardiac surgery was a risk factor in the 0.3 to 0.7 m<sup>2</sup> and >;0.7 m<sup>2</sup> BSA groups. VAD support was associated with lower WM other than in the single ventricle cohort, where VAD was associated with higher WM. Extracorporeal membrane oxygenation and mechanical ventilation were associated with increased risk of WM in all cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There is significant variability in WM among status-1A patients. Potential refinements to current allocation system should factor in the increased WM risk we identified in patients supported by extracorporeal membrane oxygenation or mechanical ventilation, single ventricle congenital heart disease on VAD support and small children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38939965</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068189>10.1161/CIRCULATIONAHA.123.068189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939965</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ryan J Butts</dc:creator>
<dc:creator>Leah Toombs</dc:creator>
<dc:creator>James K Kirklin</dc:creator>
<dc:creator>Kurt R Schumacher</dc:creator>
<dc:creator>Jennifer Conway</dc:creator>
<dc:creator>Shawn C West</dc:creator>
<dc:creator>Scott Auerbach</dc:creator>
<dc:creator>Neha Bansal</dc:creator>
<dc:creator>Hong Zhao</dc:creator>
<dc:creator>Ryan S Cantor</dc:creator>
<dc:creator>Deipanjan Nandi</dc:creator>
<dc:creator>David M Peng</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database</dc:title>
<dc:identifier>pmid:38939965</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068189</dc:identifier>
</item>
<item>
<title>Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939955/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702100904&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.068959. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel-mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Heart rate-corrected field potential duration, a surrogate for QTc, was measured in human induced pluripotent stem cells from 2 patients with LQT2 (KCNH2-p.A561V, KCNH2-p.R366X) before and after mexiletine using a multiwell multi-electrode array system. Action potential duration at 90% repolarization (APD<sub>90</sub>) was evaluated in cardiomyocytes isolated from transgenic LQT2 rabbits (KCNH2-p.G628S) at baseline and after mexiletine application. Mexiletine was given to 96 patients with LQT2. Patients were defined as responders in the presence of a QTc shortening ≥40 ms. Antiarrhythmic efficacy of mexiletine was evaluated by a Poisson regression model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After acute treatment with mexiletine, human induced pluripotent stem cells from both patients with LQT2 showed a significant shortening of heart rate-corrected field potential duration compared with dimethyl sulfoxide control. In cardiomyocytes isolated from LQT2 rabbits, acute mexiletine significantly shortened APD<sub>90</sub> (∆APD shortening 113 ms), indicating a strong mexiletine-mediated shortening across different LQT2 model systems. Mexiletine was given to 96 patients with LQT2 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexiletine only chronically and 75% of the patients who performed the acute oral test were responders. There was a significant correlation between basal QTc and ∆QTc during the test (<i>r</i>= -0.8; <i>P</i>&lt;0.001). The oral drug test correctly predicted long-term effect in 93% of the patients. Mexiletine reduced the mean yearly event rate from 0.10 (95% CI, 0.07-0.14) to 0.04 (95% CI, 0.02-0.08), with an incidence rate ratio of 0.40 (95% CI, 0.16-0.84), reflecting a 60% reduction in the event rate (<i>P</i>=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939955/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702100904&v=2.18.0.post9+e462414">38939955</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068959>10.1161/CIRCULATIONAHA.124.068959</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939955</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>Federica Dagradi</dc:creator>
<dc:creator>Giulia Musu</dc:creator>
<dc:creator>Federica Giannetti</dc:creator>
<dc:creator>J Martijn Bos</dc:creator>
<dc:creator>Miriam Barbieri</dc:creator>
<dc:creator>Paolo Cerea</dc:creator>
<dc:creator>Fulvio L F Giovenzana</dc:creator>
<dc:creator>Margherita Torchio</dc:creator>
<dc:creator>Manuela Mura</dc:creator>
<dc:creator>Massimiliano Gnecchi</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:creator>Luca Sala</dc:creator>
<dc:creator>Katja E Odening</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients</dc:title>
<dc:identifier>pmid:38939955</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068959</dc:identifier>
</item>





























</channel>
</rss>